Roivant Sciences Ltd.
ROIV
$28.58
-$0.95-3.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.26M | 13.31M | 20.33M | 23.23M | 29.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.26M | 13.31M | 20.33M | 23.23M | 29.05M |
| Cost of Revenue | 682.10M | 627.88M | 601.95M | 579.18M | 545.52M |
| Gross Profit | -673.84M | -614.57M | -581.62M | -555.94M | -516.47M |
| SG&A Expenses | 605.87M | 660.49M | 617.78M | 684.54M | 649.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.29B | 1.29B | 1.22B | 1.26B | 1.19B |
| Operating Income | -1.28B | -1.28B | -1.20B | -1.24B | -1.17B |
| Income Before Tax | -264.58M | -921.73M | -865.87M | -931.21M | -681.59M |
| Income Tax Expenses | 133.33M | 84.30M | 35.40M | 40.86M | 48.17M |
| Earnings from Continuing Operations | -397.91 | -1.01K | -901.27 | -972.07 | -729.76 |
| Earnings from Discontinued Operations | -- | 0.00 | 327.02M | 283.94M | 373.03M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 98.14M | 196.79M | 200.28M | 197.50M | 184.75M |
| Net Income | -299.77M | -809.24M | -373.97M | -490.63M | -171.98M |
| EBIT | -1.28B | -1.28B | -1.20B | -1.24B | -1.17B |
| EBITDA | -1.28B | -1.26B | -1.19B | -1.23B | -1.15B |
| EPS Basic | -0.45 | -1.17 | -0.55 | -0.70 | -0.24 |
| Normalized Basic EPS | -0.89 | -0.73 | -0.63 | -0.61 | -0.53 |
| EPS Diluted | -0.60 | -1.18 | -0.56 | -0.70 | -0.24 |
| Normalized Diluted EPS | -0.84 | -0.73 | -0.63 | -0.61 | -0.52 |
| Average Basic Shares Outstanding | 2.76B | 2.77B | 2.79B | 2.85B | 2.90B |
| Average Diluted Shares Outstanding | 2.87B | 2.77B | 2.79B | 2.85B | 2.95B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |